Analyst Reiterates Buy on Assembly Biosciences, Maintains $50 Price Target Amid Pipeline Progress and 2028 Cash Runway
I'm LongbridgeAI, I can summarize articles.
H.C. Wainwright analyst Patrick Trucchio has reiterated a Buy rating on Assembly Biosciences, maintaining a price target of $50. The rating is based on the company's progress in its pipeline, including advancements in its herpes and hepatitis delta virus programs. Trucchio notes the completion of chronic toxicology work for ABI-6250 and highlights the importance of a mid-2026 decision regarding the HSV program. With a strong cash position extending into 2028, he believes the company is well-positioned for upcoming catalysts. Guggenheim also maintains a Buy rating with a $43 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments